October 28, 2021
Sumitomo Dainippon Pharma will accelerate its development in the CNS space through a worldwide collaboration with Otsuka Pharmaceutical announced late last month. The company will initially focus on the development of SEP-363856 (ulotaront) for the treatment of schizophrenia, but plans...read more